There are quite a few posters at the forthcoming AACR-NCI-EORTC Molecular Targets meeting this weekend that I wanted to highlight as potentially interesting and will additionally review in more depth once they have been published.
Please note: None of the embargoed abstracts are covered here in this preview to avoid any complications, but more detailed notes and reports will follow later on these from the conference as they are published.
Here some of the abstracts that caught my eye, in no particular order:
Subscribers can log-in to read our latest insights or you can purchase access to BSB Premium Content.
In her annual preview video of what’s hot at ASCO 2013, Sally Church (@Maverickny) discusses several therapeutic areas with new data at the meeting including:
- Immunotherapy (PD-1, PD-L1, CTLA-4)
- CLL (GA-101, idelalisib, IPI-145)
- Breast Cancer (palbociclib, PF-05280014)
- Lung Cancer (LDK-378, AP26113)
- Pancreatic Cancer (Abraxane, TH-302)
This video was originally published on Pharma Strategy Blog and includes an edited mechanism of action (MOA) for PD-L1 (courtesy of Roche/Genentech). Several people have since remarked it’s the first time they fully understood what “upregulation” meant.
If you missed the video, it’s well worth watching again in the run up to ASCO 2014.